Long-term cardiovascular risk following platinum-based chemotherapy for germ cell tumors

Future Oncology

Volumn 6, Issue 9, 2010, Pages 1365-1368

  Evans, Clary ^a   Williams, Michael ^a   Mazhar, Danish ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

cardiovascular disease; chemotherapy; cisplatin; germ cell tumor; long term

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; GERM CELL TUMOR; HEART INFARCTION; HUMAN; MORBIDITY; PRIORITY JOURNAL; SMOKING;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CISPLATIN; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK FACTORS;

EID: 77957936200     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.119     Document Type: Editorial

References (12)

1. Vogelzang NJ, Bosel GJ, Johnson K et al.: Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann. Intern. Med. 95, 288-292 (1981).
2. Meinardi MT, Gietema JA, van der Graf WT et al.: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18, 1725-1732 (2000).
3. Huddart RA, Norman A, Shahidi M et al.: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513-1523 (2003).
4. Van den Belt-Dusebout AW, Nuver J, de Wit R et al.: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 24, 467-475 (2006).
5. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T: The long-term risks of adjuvant carboplatin treatment for stage 1 seminoma of the testis. Ann. Oncol. 19, 443-447 (2008).
6. Van den Belt-Dusebout AW, de Wit R, Gietema JA et al.: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370-4378 (2007).
7. Gietema JA, Meinardi MT, Messerschmidt J et al.: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355, 1075-1076 (2000).
8. Vaughn DJ, Palmer SC, Carver JR et al.: Cardiovascular risk in long-term survivors of testicular cancer. Cancer 112, 1949-1953 (2008).
9. Alterna R, de Hass EC, Nuver J et al.: Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br. J. Cancer 100, 1861-1866 (2009).
10. Sagstuen H, Aass N, Fossa SD et al.: Blood pressure and body mass index in long-term survivors of testicular cancer. J. Clin. Oncol. 23, 4980-4990 (2005).
11. Bokemeyer C, Berger CC, Kuczyk MA et al.: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J. Clin. Oncol. 14, 2923-2932 (1996). (Pubitemid 26371450)
12. Gietema JA, Sieijfer DT, Willemse PH et al.: Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann. Intern. Med. 116(9), 709-715 (1992).